Listing & Compliance Notices

BRC Group Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“March 18, 2024, B. Riley Financial, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”). The Notice states that the Company has 60 calendar days from the da”

Workhorse Group Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 21, 2024, the Company received written notification from the Listing Qualifications Department of Nasdaq (the “Extension Notice”), granting the Company’s request for a 180-day extension to regain compliance with the Bid Price Requirement. The Company now has until September 16, 2024, to meet the Bid Price Requirement. If at any time prior to September 16, 2024, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive trading days, the Company will regain compliance with the Bid Price Requirement. The Extension Notice has no immediate e”

Sonoma Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 21, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until September 16, 2024 to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Rule”). The Extension Notice has no immediate effect on the listing of the Company’s common stock. As previously disclosed in the”

SUNPOWER CORP received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“March 20, 2024, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-K with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq. The Notice also indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days”

TREASURE GLOBAL INC received a nasdaq deficiency notice notice regarding shareholders (rules 5635(c)).

“March 20, 2024, Treasure Global Inc (the “Company”) received a written notice from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) dated March 20, 2024, notifying the Company that (1) it was not in compliance with the shareholder approval requirement of Nasdaq Listing Rule 5635(c) (the “Rule”) because on October 11, 2023, the Company issued restricted shares in the aggregate amount of 1,816,735 in exchange for the cancellation of $321,562.08 of debt, resulting in an effective price per share of $0.176, 1,057,519 of such shares were issued to Chong Chan Teo, the Company’s Chief Executive Of”

Alternus Clean Energy, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 20, 2024, Alternus Clean Energy, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market notifying the Company that, because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business days, it no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimu”

LAMF Global Ventures Corp. I received a nasdaq deficiency notice notice regarding other (rules 5450(a)(2)).

“March 18, 2024, LAMF Global Ventures Corp. I (the “Company”) received a letter (the “Notice”) from the Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with the requirements of Nasdaq Listing Rule 5450(a)(2) (the “Rule”) for continued listing on Nasdaq. Under the Rule, the Company is required to maintain at least 400 total holders (the “Total Holder Requirement”). The Notice indicates that the Company has 45 calendar days (the “Deadline”) to submit a plan (the “Compliance Plan”) to regain compliance with the Rule. If”

Angel Studios, Inc. received a nyse delisting notice notice regarding market value (rules 802.01).

“rrants, with each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50, subject to adjustment (the “Warrants”) and (iii) units, each consisting of one share of Class A Common Stock and one-half of one Warrant (the “Units”), from the NYSE pursuant to Section 802.01 of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly held shares over a consecutive 30 trading day period”

CuriosityStream Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 19, 2024, the Company received written notification from the Listing Qualifications Department of Nasdaq, granting the Company's request for a 180-day extension to regain compliance the Bid Price Rule. The Company now has until September 16, 2024, to meet the requirement. If at any time prior to September 16, 2024, the bid price of the Company's Common Stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule during the additional 180-”

Triller Group Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 20, 2024, the Company received a letter from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until September 16, 2024, (the “Second Compliance Period”) to regain compliance. If at any time during the Second Compliance Period, the closing bid price of the Company’s ordinary share is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide the Company with written confirmation of compliance.”

TaoWeave, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 21, 2023, Oblong, Inc., a Delaware corporation (the “ Company ”), received written notice (the " Notice ") from the Nasdaq Stock Market, LLC (" Nasdaq ") indicating that the bid price for the Company's common stock (the "Common Stock"), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the " Bid Price Rule "). On March 20, 2024, the Company received”

Avid Bioservices, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“March 19, 2024, Avid Bioservices, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024 (the “Form 10-Q”) in a timely manner. The Rule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (th”

Thunder Power Holdings, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5450(a)(2)).

“ilure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March18, 2024, FLFV received a written notice (the “ Notice ”) from the listing qualifications department staff of The Nasdaq Stock Market (“ Nasdaq ”) notifying FLFV that the FLFV was not in compliance with Listing Rule 5450(a)(2) (the “Minimum Holders Rule”), which requires FLFV to have at least 400 total holders for continued listing on the Nasdaq Global Market. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the FLFV’s securities”

AIB Acquisition Corp received a nasdaq hearing update notice regarding market value (rules 5450(b)(2)(A), 5450(b)(3)(C), 5450(a)(2)).

“mbination, (ii) on or before May 15, 2024, the Company holds a shareholder meeting and obtain approval for completion of its initial business combination; and (iii) on or before May 20, 2024, the Company closes its initial business combination and the new entity demonstrates compliance with Listing Rule 5505. As previously disclosed, the Company originally received two deficiency letters from the Nasdaq Listing Qualification Department (the “Staff”) on May 11, 2023, notifying the Company that, for the preceding 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVL”

Corner Growth Acquisition Corp. received a nasdaq deficiency notice notice regarding other (rules IM-5101-2).

“March 15, 2024, the Nasdaq Hearings Panel issued written notice of its decision to grant the Company’s request for an exception to its listing deficiencies until June 17, 2024 in view of the Company’s substantial steps toward closing its previously announced initial business combination and its plan for achieving compliance with Nasdaq listing rules upon closing of the transaction for listing on The Nasdaq Capital Market. No Offer or Solicitation This communication relates to the proposed business combination between Noventiq Holdings PLC (“Noventiq”) and Corner Growth (the “Business Combinati”

InMed Pharmaceuticals Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 19, 2024, the Company received written notification (the “Current Notification”) from the Listing Qualifications Department of Nasdaq that the Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the “Extended Compliance Period”), to regain compliance with the Minimum Bid Price Rule. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement”

ASPAC II Acquisition Corp. received a nasdaq noncompliance notice notice regarding other (rules 5450(a)(2)).

“March 15, 2024, A SPAC II Acquisition Corp. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), which stated that the Company no longer complies with Nasdaq’s continued listing rules on The Nasdaq Global Market due to the Company not having maintained a minimum of 400 public holders for continued listing, as required pursuant to Nasdaq Listing Rule 5450(a)(2). In accordance with the Nasdaq listing rules, the Company has 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq can grant the Company an extension of up to 180 calend”

Aetherium Acquisition Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5450(a)(2)).

“the Staff provided written notice to the Company does not comply with Listing Rule 5250(c) because it did not file its Form 10-Q for the period ended September 30, 2023. In addition, Staff has determined that the Company does not comply with the minimum 400 total holders as required by Listing Rule 5450(a)(2). On December 4, 2023, the Company appealed the delist determination to the Nasdaq Hearings Panel (the “ Panel ”), and requested that the stay of delisting, which otherwise would expire on December 19, 2023, pursuant to Rule 5815(a)(l)(B), be extended until the Panel issued a final decisio”

Aetherium Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“February 8, 2024, Aetherium Acquisition Corp. (the “ Company ”) received written notice from the Nasdaq Listing Qualifications staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with the continued listing requirement to maintain a minimum Market Value of Listed Securities (“ MVLS ”) of $50,000,000, as set forth in Nasdaq Listing Rule 5450(b)(2)(A). In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company received 180 calendar days, until November 6, 2023, to regain compliance with the minimum MVLS requirement. To regain compliance”

Bolt Projects Holdings, Inc. received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“March 18, 2024, Golden Arrow Merger Corp. (the “Company”) received a notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”), trading of the Company’s securities on The Nasdaq Capital Market would be suspended at the opening of business on March 27, 2024, due to the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the eff”

Chemours Co received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“March 18, 2024, the New York Stock Exchange (the “NYSE”) notified The Chemours Company (the “Company”) that it is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”). In accordance with the NYSE Listed Company Manual, the Company has contacted the NYSE to discuss the status of its Form 10-K filing. On March 18, 2024, the Company issued a press release with respect to the receipt of the notice of noncompliance from the NYSE. A copy of the press rel”

Zoomcar Holdings, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605, 5605(b)(1)(A)).

“March 12, 2024, the Company received a notice (“ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that, as a result of the resignation of David Ishag from the board of directors of the Company (the “ Board ”), effective January 30, 2024, the Company is no longer in compliance with the continued listing requirements set forth in Nasdaq Listing Rule 5605, which requires that a majority of the Board be comprised of independent directors. The Notice is only a notification of deficiency, not of imminent delisting, and has no cur”

Virpax Pharmaceuticals, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“March 15, 2024, Virpax Pharmaceuticals, Inc. (the “Company”), received a letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that for the last 10 consecutive business days, from March 1, through 14, 2024, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed .”

Streamex Corp. received a nasdaq delisting notice notice regarding board independence (rules 5101, 5605).

“March 12, 2024, the Company received a letter from the Staff stating that based upon the Staff’s review of the Company and pursuant to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a “public shell,” and that the continued listing of its securities is no longer warranted, in view of the following: ● On February 5, 2024, the Company disclosed in a Form 8-K that the Company commenced a workforce reduction consisting of 16 employees including the Chief Operating Officer and the Chief Commercial Officer; ● On February 21, 2024, the Company disc”

Streamex Corp. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(2)).

“March 5, 2024, BioSig Technologies, Inc. (the “Company”) received a letter from the Listing Qualifications Department of Nasdaq (the “Staff”) stating that the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company’s common stock did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market, and the Company is not eligible for a second 180 day cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capit”

ATOSSA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“March 15, 2024, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously disclosed, on September 26, 2023, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company was”

AI Financial Corp received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“March 13, 2024 (the date of this Current Report on Form 8-K), JanOne Inc. (“we” or “us”) presently complies with Nasdaq Listing Rule 5550(a)(2) that requires us to maintain a minimum bid price of $1.00 per share. As previously reported, on September 11, 2023, we received a notice (the “Deficiency Notice”) from The Nasdaq Stock Market (“Nasdaq”), indicating that our common stock failed to maintain a minimum bid price of $1.00 per share over the previous 30 consecutive business days as required by the Nasdaq Listing Rules. On March 13, 2024, we received a notice (the “Compliance Notice”) from Na”

TEAM INC received a nyse deficiency notice notice regarding stockholders equity (rules 802.01B).

“March 14, 2024, Team, Inc. (the “Company”) received a written notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the continued listing standards set forth in Rule 802.01B of the NYSE Listed Company Manual because its average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported shareholders’ equity was less than $50 million. As required by the NYSE, the Company intends to timely notify the NYSE of its intent to cure the deficiency and restore its compliance with the N”

TEAM INC received a nyse deficiency notice notice regarding market value (rules 802.01B).

“March 14, 2024, Team, Inc. (the “Company”) received a written notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the continued listing standards set forth in Rule 802.01B of the NYSE Listed Company Manual because its average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its last reported shareholders’ equity was less than $50 million. As required by the NYSE, the Company intends to timely notify the NYSE of its intent to cure the deficiency and restore its compliance with the N”

AMC Robotics Corp received a nasdaq deficiency notice notice regarding board independence (rules 5615(b)(1), 5605(c)(2)(A)).

“March 11, 2024, AlphaVest Acquisition Corp (the “Company”) was contacted by the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”). The Staff notified the Company that it was not in compliance with the Nasdaq continuing listing standard following the termination of the phase-in period provided under Nasdaq Listing Rule 5615(b)(1) and 5605(c)(2)(A) regarding the composition of the Company’s Board of Directors (the “Board”) and the Audit Committee, respectively, because a majority of the Board was not comprised of independent directors and the Audit Committee was not comprised of at l”

NKGen Biotech, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“March 11, 2024, NKGen Biotech, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the Company’s Market Value of Listed Securities (as defined under Nasdaq rules) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has”

Mediaco Holding Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 14, 2024, MediaCo Holding Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had been granted an additional 180 days, or until September 9, 2024, to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), based on the Company meeting the continued listing requirement for m”

Kaival Brands Innovations Group, Inc. received a nasdaq deficiency notice notice regarding board independence.

“March 13, 2024, Kaival Brands Innovations Group, Inc. (the “Company,” “we” or “us”), received a letter from the Listing Qualifications Department (the “Staff”) of The NASDAQ Stock Market (“Nasdaq”) notifying the Company that, as a result of the resignation of Mr. John Brooks and Mr. George Chuang as directors of the Company (as described in”

CURO Group Holdings Corp. received a nyse delisting notice notice regarding market value (rules 802.01B).

“March 11, 2024, the New York Stock Exchange (the “NYSE”) notified CURO Group Holdings Corp. (the “Company”), and publicly announced, that it had determined to commence proceedings to delist the Company’s common stock, par value $0.001 per share (the “Common Stock”), as a result of the Company’s non-compliance with Rule 802.01B of the NYSE Listed Company Manual, which requires listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15 million. Trading in the Common Stock on the NYSE was suspended after market close on March 11”

Custom Truck One Source, Inc. received a nyse delisting notice notice regarding other (rules 802.01D).

“March 14, 2024, the New York Stock Exchange (the “NYSE”) notified Custom Truck One Source, Inc. (the “Company”), and on March 15, 2024, publicly announced, that the NYSE has determined to (a) commence proceedings to delist the Company’s redeemable warrants listed on the NYSE under the ticker symbol “CTOS.WS,” each exercisable to purchase one share of the Company’s common stock at a price of $11.50 per share (the “Warrants”) and (b) immediately suspend trading in the Warrants due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company”

HYDROFARM HOLDINGS GROUP, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 14, 2024, Hydrofarm Holdings Group, Inc (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days, the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Global Select Market under t”

Zomedica Corp. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v)).

“March 13, 2024, Zomedica Corp. (the “Company”) announced that it was continuing its dialogue with the NYSE American LLC (the “NYSE American”) regarding next steps associated with the deficiency letter (the “Letter”) the Company received from NYSE American on September 12, 2023. As reported in a prior Form 8-K, the Letter indicated that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company’s common shares were trading for a substantial period of time at a l”

MUSTANG BIO, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 13, 2024, Mustang Bio, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Annual Report on F”

Exela Technologies, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

“f The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2022 fiscal year end.”

2U, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 14, 2024, 2U, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), was below the $1.00 per share minimum required for continued listing on Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”). The notification has no immediate effect on the listing of the Common Stock, which continues”

KUSTOM ENTERTAINMENT, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

“March 14, 2024, the Nasdaq Listing Qualifications staff notified Digital Ally, Inc. (the “Company”), that due to resignation of Mr. Michael J. Caulfield from the Company’s board of directors (the “Board”) effective on January 31, 2024, the Company no longer complies with the audit committee and compensation committee requirements as set forth in Listing Rule 5605 of The Nasdaq Stock Market LLC (“Nasdaq”), including the requirements that there are at least three independent directors on the Company’s audit committee and at least two independent directors on the Company’s compensation committee.”

Infinera Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“March 15, 2024, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the Company is delinquent in filing its Form 10-K, the Company no longer complies with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. In accordance with the Nasdaq Listing Rules, the Company has 60 calendar days after Nasdaq’s notice, or May 14, 2024, to submit a plan of compliance (the “Plan”) addressing how it intends to regain compliance w”

PepperLime Health Acquisition Corp received a nasdaq deficiency notice notice regarding audit committee (rules 5605).

“March 11, 2024, PepperLime Health Acquisition Corporation (the “Company”) received a notice (the “Nasdaq Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that as a result of Ms. Michelle Fang’s resignation from the Company’s board of directors in January 2024, the Company no longer complies with Nasdaq’s audit committee requirement as set forth in Nasdaq Listing Rule 5605, including the requirement that there are at least three independent directors on the Company’s audit committee. The Company is provided a cure period until the earlier of the Company’s next annual shareholders’”

Better Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price.

“March 14, 2024. On March 14, 2024, the Company has voluntarily requested a delisting of its securities and expects its securities to be delisted in the near term. The Company further intends to file a Form 15 with the Securities and Exchange Commission to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended.”

Bakkt, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“March 13, 2024, Bakkt Holdings, Inc. (“ Bakkt ” or the “ Company ”) was notified by NYSE Regulation Inc. (the “ NYSE ”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual (the “ Listing Rule ”) because the average closing stock price of a share of the Company’s Class A common stock was less than $1.00 per share over a consecutive 30 trading-day period. Pursuant to the Listing Rule, the Company has six months following the NYSE notification to regain compliance with the Listing Rule, during which time the Company’s Class A common stock will continue to be listed”

DNA X, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 13, 2024, Sonim Technologies, Inc. (the “Company”) received formal notice that The Nasdaq Stock Market, LLC (“Nasdaq”) granted the Company’s request for an additional 180-day period, or until September 9, 2024, (the “Extension Notice”) from the Listing Qualifications Department (the “Staff”) to evidence compliance with the $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). If at any time before September 9, 2024, the bid price of the Company’s common stock closes at $1.00 per share or”

PLUS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 8, 2024, Plus Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it no longer complies with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Equity Standard”) or the alternative requirements of having a market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or”

Citius Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“March 12, 2024, Citius Pharmaceuticals, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted our request for an extension through September 9, 2024 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). If at any time before September 9, 2024, the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written co”

BIO-PATH HOLDINGS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 12, 2024, Bio-Path Holdings, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock will continue to trade on The Nasdaq C”

BioCardia, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an initial period of 180 calendar days, or until March 11, 2024 (the “Minimum Bid Price Compliance Date”), to regain compliance with”